CONMED Corp CNMD
NYSE · XNYS · stock · Electromedical & Electrotherapeutic Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
2.97
Altman Z″ — distress risk · safe
52.6%
Dividend payout · moderate
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.4B | $47.1M | $750.5M | $150.9M | $1.0B |
| 2024 | $1.3B | $132.4M | $733.0M | $153.9M | $962.7M |
| 2023 | $1.2B | $64.5M | $676.2M | $106.3M | $834.2M |
| 2022 | $1.0B | -$80.6M | $571.2M | $11.6M | $745.5M |
| 2021 | $1.0B | $62.5M | $568.0M | $96.9M | $785.4M |
| 2020 | $862.5M | $9.5M | $460.3M | $51.5M | $709.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Bronson David M. | director | 2026-06-02 | Option exercise | 668 | — |
| Council LaVerne H | director | 2026-06-02 | Option exercise | 668 | — |
| Farkas Charles | director | 2026-06-02 | Option exercise | 668 | — |
| Kaye Mark | director | 2026-06-02 | Option exercise | 668 | — |
| Schwarzentraub Barbara J | director | 2026-06-02 | Option exercise | 668 | — |
| Lalomia Brent | Executive VP RA, QA | 2026-03-06 | Option exercise | 75 | — |
| Lalomia Brent | Executive VP RA, QA | 2026-03-06 | Tax withheld | 26 | $39.90 |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.97 (safe)
- Working capital / assets 0.154
- Retained earnings / assets 0.253
- EBIT / assets 0.044
- Equity / liabilities 0.799
Source: SEC EDGAR filings · CIK 0000816956 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.